Table 3.
Specific gallbladder findings (per Independent Ultrasound Review)
| |
Arm A |
Arm B |
Arm C |
||||||
|---|---|---|---|---|---|---|---|---|---|
| |
Motesanib 125 mg QD |
Motesanib 75 mg BID |
Motesanib 75 mg BID |
||||||
| |
|
2 wk on/1 wk off |
5 d on/2 d off |
||||||
|
Patient incidence, n (%) |
Baseline |
Post baseline* |
Post treatment† |
Baseline |
Post baseline* |
Post treatment† |
Baseline |
Post baseline* |
Post treatment† |
| (n = 23) | (n = 23) | (n = 16) | (n = 11) | (n = 11) | (n = 9) | (n = 11) | (n = 11) | (n = 8) | |
| Gallstones |
3 (13) |
4 (17) |
3 (19) |
3 (27) |
2 (18) |
2 (22) |
0 (0) |
0 (0) |
0 (0) |
| Sludge |
0 (0) |
9 (39) |
4 (25) |
0 (0) |
4 (36) |
4 (44) |
0 (0) |
3 (27) |
0 (0) |
| Pericholecystic fluid |
0 (0) |
1 (4) |
0 (0) |
1 (9) |
1 (9) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
| Common duct dilation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
*Data within the table indicate number of patients with at least one incidence of the specific gallbladder findings listed at any point during postbaseline treatment.
†Data within the table indicate number of patients who had the specific gallbladder findings listed at their last available off-treatment assessment.